The future of experimental medicine is not simply a regulatory question. It is a question about who controls access, who pays for treatment, who generates evidence, and who bears the risk. We spend too much time debating what will happen in healthcare. We hold conferences on “future-proofing” pharma. We run scenario-planning exercises on the FDA…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
